{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-021658","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.151697+00:00","generated_at":"2026-06-05T09:59:18.404479+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Geron reports Q4/FY2023 results; cash $378M, PDUFA June 16, 2024 for imetelstat","bullets":["Cash, cash equivalents and marketable securities of $378.1M as of Dec 31, 2023; cash runway into Q3 2025.","FDA PDUFA action date June 16, 2024 for imetelstat NDA in transfusion-dependent LR-MDS; ODAC meeting March 14, 2024.","Total operating expenses FY2023: $194.1M (R&D $125M, G&A $69.1M); FY2024 guidance $270-280M.","Phase 3 IMpactMF for myelofibrosis achieved 50% enrollment; interim analysis expected H1 2025.","Revenue minimal at $237,000 for FY2023; company plans to grow to ~270 employees by end of 2024 if approved."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-021658","json":"https://secwatch.observer/filing/0000950170-24-021658.json","markdown":"https://secwatch.observer/filing/0000950170-24-021658.md","text":"https://secwatch.observer/filing/0000950170-24-021658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000095017024021658/0000950170-24-021658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000095017024021658/gern-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:59:18.404479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c5e096c735ec0c30b018e6463cbbc8b828fbb48f","claim":"GERON CORP reported the fourth quarter and full year 2023 results: revenue $23,000 and $237,000, respectively.","evidence_excerpt":"loan facility, will be sufficient to fund its projected operating expenses into the third quarter of 2025. Revenues for the three and twelve months ended December 31, 2023, were $23,000 and $237,000, respectively, compared to $103,000 and $596,000 for the comparable 2022 periods. Revenues in both years primarily reflect estimated royalties from sales of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886744/000095017024021658/0000950170-24-021658-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2023"},{"label":"Revenue","value":"$23,000 and $237,000, respectively"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}